Board of Directors
The Urology Care Foundation Board of Directors' governance structure is led by the Foundation President and includes AUA member urologists and public directors. The extensive knowledge of this group will be invaluable as the Foundation forges ahead in its efforts to pave a way for advancements in urologic research and patient care.
Harris M. Nagler, MD, FACS
Professor of Urology at Hofstra Northwell School of Medicine
Dr. Nagler previously served as President of Beth Israel Medical Center and Chair of the Sol and Margaret Berger Department of Urology at Beth Israel Medical Center and Professor of Urology at the Icahn School of Medicine at Mount Sinai. At Beth Israel he had also served as the Chief of Graduate Medical Education/Academic Affairs at the Beth Israel; the Program Director of the urology residency-training program, Chief Medical Officer and Physician-in-Chief. Dr Nagler's clinical practice focuses on male infertility, erectile dysfunction and general urology.
Gopal H. Badlani, MD
Wake Forest Baptist Medical Center
Dr. Badlani is currently professor of urology, vice chair for clinical affairs, and director of the Urogynecology Regenerative Medicine Program at Wake Forest Baptist Medical Center in Winston-Salem, NC. He most recently served as the American Urological Association (AUA) Secretary where he supported the Urology Care Foundation chair, Dr. Memo and the BOD with the Foundation's outreach and development programs. Through his tireless efforts, he helped establish 14 new Research Endowment awards through the Research Scholars Award Program, the flagship research training program of the Foundation.
In 2013, Dr. Badlani was one of three physicians nationwide selected to receive a Physician of the Year Award for Clinical Excellence from Castle Connolly Medical Ltd. The award recognizes physicians who exemplify excellence in clinical medical practice.
David F. Green, MD, FACS
Chief medical officer at Concord Hospital
Dr. Green is a senior partner at Concord Hospital’s Center for Urologic Care. He is also an adjunct associate professor of surgery with the Dartmouth Medical School. Since 2014, he has served as CEO of NH Accountable Care Partners, LLC. Dr. Green has been active in the AUA’s New England Section throughout his career serving as a committee chair and later served as a state representative, secretary and president of the Board of Directors.
On the national level, Dr. Green has served the AUA in various capacities including serving on the Manpower Committee in 1995, serving on the Women in Urology Committee and chairing this between 1996 and 2001. He has served on the Bylaws Committee, the Public Relations Committee and the Audit Committee serving as its Chair in 2012, and was the New England Section Representative to the AUA Board of Directors from 2009 to 2013. From 2012-2013, he served as the Secretary of UROPAC.
Arthur L. “Bud” Burnett, II, MD, MBA, FACS
Professor of Urology and Director of the Basic Science Laboratory in Neuro-urology at Johns Hopkins University School of Medicine
Dr. Burnett is recognized as a world-authority in the science and medicine of male erectile dysfunction and has contributed several original discoveries which have paved the way for the clinical development of oral medications to treat erectile dysfunction. His areas of expertise include prostate cancer, lower genitourinary tract malignancies and reconstruction, erectile dysfunction, penile abnormalities and female urology.
His extensive history with the Urology Care Foundation dates back more than 25 years when he first received a New Investigator Research Award in 1994. Since then, he has gone on to mentor six Foundation research awardees, for which he received the Foundation’s Distinguished Mentor Award in 2016. He most recently served on the Foundation’s Public Education Council and as Chair of the Foundation’s Reproductive and Sexual Health Committee.
Ralph V. Clayman, MD
Co-founder of the Endourology Society
Dr. Clayman is a Distinguished Professor of Urology in the Department of Urology at UC Irvine and occupies an endowed Chair in Endourology. He also continues to serve as co-editor of the Journal of Endourology. Dr. Clayman has an active clinical practice in urolithiasis and co-directs the endourology research laboratory and endourology fellowship program at UC Irvine.
In January 2002, he became the Chair of the newly formed Department of Urology at the University of California – Irvine, and in 2009, he became Dean of the School of Medicine at UC Irvine. In 2016, he published a book regarding academic leadership entitled, “The Compleat Dean” which has sold over 1,000 copies. He holds 13 patents on devices/instruments used in minimally invasive surgery and has published over 440 peer reviewed manuscripts.
Sanford J. Seigel, MD
Founder of Chesapeake Urology Associates
Dr. Siegel was elected President and CEO of the new Chesapeake Urology Associates in 2006 when Baltimore’s three largest urology practices merged. As President and CEO of Chesapeake Urology, Dr. Siegel has built the group into one of the country’s most prominent urology practices, and the largest in the Mid-Atlantic Region. Dr. Siegel also served on the board of directors for ZERO – The End of Prostate Cancer and currently is a board member of the Park Heights Community Health Alliance (PHCHA).
Mary Ann Lynn Stothers, MD, MHSc
Professor at the University of British Columbia in the Department of Urologic Sciences
Dr. Stothers serves as Associate Member of the School of Population and Public Health; Associate Member of the Department of Anesthesiology, Pharmacology and Therapeutics; and Associate Member of the Department of Obstetrics and Gynecology.
Dr. Stothers is a principal investigator at the International Collaboration on Repair Discoveries (ICORD), where she has a keen interest in the results and challenges following spinal cord injury. She is committed to her work with hospital foundations and other nonprofits and has been involved in raising funds for urology research and care for more 20 years. She enjoys her time volunteering with the Rick Hansen Institute and helping to raise funds for spinal cord injury research and education.
Larry Lipshultz, MD
Professor of Urology and Chief of the Scott Department of Urology's Division of Male Reproductive Medicine and Surgery
Dr. Lipshultz, who holds the Smith Chair in Reproductive Medicine, is a well-known authority on abnormalities of male reproduction, erectile dysfunction, and male hormone production. He also is the AUA's first Research Scholar.
Recognized as a leading expert on men's health, Dr. Lipshultz is a highly respected author and editor, as well as lecturer. His research has been in many journals, books and videos. Dr. Lipshultz instituted a fellowship training program in male reproductive medicine and surgery that has trained more than 80 physicians who are now in practice both in the U.S. and abroad.
Joseph A. Smith, MD
William L. Bray Professor in the Department of Urology at Vanderbilt University
Dr. Smith served as Chairman of the department from 1991 to 2015. Dr. Smith has served as President of the American Board of Urology, President of the Society of Urologic Oncology, President of the Southeastern Section of the American Urologic Association, and Chairman of the Residency Review Committee for Urology. He is a recipient of the Distinguished Contribution Award and the Hugh Hampton Young Award from the AUA. Dr. Smith is Editor of the Journal of Urology, the most widely read and highly cited journal in the specialty. He has been listed on Castle Connelly prestigious “Best Doctors” list for 25 consecutive years and was designated by Time Magazine as one of the top five surgeons in the country for treatment of cancer. His professional focus has been on innovative treatment strategies for patients with urologic cancers and introduction and evaluation of technologic advances in urologic surgery. He has performed over 1,000 radical cystectomies and 8,000 radical prostatectomies.
Jay G. Baitler
Operating Partner with Atlas Holdings
Mr. Baitler is currently an operating partner with Atlas Holdings, a private equity firm and diversified group of manufacturing, distribution, service and trading businesses. Prior to Atlas Holdings, Mr. Baitler served as Executive Vice President, Staples Contract Division, from 2004 until his retirement in 2013. During his tenure with Staples, Mr. Baitler oversaw significant growth of the organization, both organic and acquired, and was personally responsible for the integration of Corporate Express, a $4.4 billion acquisition, the largest acquisition in Staples' history. He has been Independent Director of TESSCO Technologies Inc. since 2007 and is also a Director of Iconex.
Mr. Baitler has served on many Boards, including the Board of Managers at Soundview Paper, LLC and the Advisory Boards of Finch Paper, LLC and Twin Rivers Paper Company. Mr. Baitler is a graduate of Union College and currently resides in Palm Beach Gardens, FL.
Ryan D. Drant
Founder and Managing Director of Questa Capital Management
Mr. Drant specializes in healthcare investments in the medical device, healthcare services, healthcare information technology and specialty pharma sectors, and has been actively investing in healthcare since 1996. During his investment career, he has served on 33 boards of directors and has overseen the deployment of $950 million in equity capital. Mr. Drant was named four times to the Forbes Midas List of best venture capital investors.
Prior to founding Questa, Mr. Drant was a General Partner at New Enterprise Associates (NEA), where he joined in 1996, became a General Partner in 2004 and served on the firm's investment committee for 11 years spanning four funds totaling $8.0 billion in total capital. He led the firm's global healthcare investing practice and served as a member of NEA's four-person management committee. Previously, Mr. Drant was with the Health Care Investment Banking Group of Alex. Brown & Sons and Arthur Andersen & Co. Mr. Drant graduated from Stanford University with a BA in Political Science.
HPE Financial Services (HPEFS), the IT investment and financing subsidiary of Hewlett Packard Enterprise (HPE)
Mr. Rothman leads HPE Financial Services (HPEFS), the IT investment and financing subsidiary of Hewlett Packard Enterprise (HPE). Mr. Rothman is responsible for the worldwide delivery of solutions that enable business transformation.
Prior to joining HPEFS, Mr. Rothman was President and CEO of Compaq Financial Services Corporation (CFS). He led CFS from its founding in 1997, growing the business to greater than $3.7 billion in assets generating over $1.0 billion in revenue prior to the HP-Compaq merger which was completed in 2002.
With over 44 years in the financial services industry, Mr. Rothman has held leadership positions with U.S. Leasing International and Thomson McKinnon Securities before joining AT&T in 1985. As a group president of AT&T Capital Corporation, he helped build an organization that ultimately grew to be the second largest leasing company in the US.
Amarpreet Sawhney, PhD
Chairman of Ocular Therapeutix, Inc.
Dr. Sawhneyis the Chairman of Ocular Therapeutix, Inc., a company focused on solving unmet needs in ophthalmic drug delivery and wound sealing. He is also the Chief Executive Officer and Chairman of Instylla, Inc., a company focused on liquid embolic products for interventional oncology. His entrepreneurism has facilitated the creation of several bio-pharma and medical device companies, as well as the development of such innovative technology solutions as extravascular closure devices, surgical sealants and spacers that enable improved radiotherapy. Dr. Sawhney’s innovations are the subject of more than 120 issued and pending patents in medical devices, methods, and biomaterials. Many of his innovations have been “first of a kind” to be approved by the U.S. Food and Drug Administration.
He has been involved in several charitable causes including ones focused on education, the environment and creating platforms to support other healthcare entrepreneurs. Through his companies and inventions, Dr. Sawhney has touched more than five million patients and created more than 2,000 jobs.